国产91传媒,500av导航大全精品,日韩成人欧美

Johnson & Johnson Full Year 2025 Financial Report Johnson & Johnson Johnson & Johnson posts steady 2025 growth with $94.2B revenue, driven by pharmaceuticals ($60.4B) and medical technology. Strong innovation and global performance set a positive outlook for 2026.
Johnson & Johnson 2025 Q2 Earnings Report Financial statements Johnson & Johnson's Q2 2025 earnings report highlights strong growth across Innovative Medicine and MedTech, driven by oncology breakthroughs and cardiovascular innovation despite industry headwinds.
Johnson & Johnson 2025 H1 Performance Financial statements Johnson & Johnson reports $45.64B revenue in H1 2025, driven by oncology growth. Darzalex hits $6.8B, Carvykti surges toward $2B. Neuroscience and immunology portfolios evolve amid strategic acquisitions.
Johnson & Johnson's Q1 2025 Financial report Johnson & Johnson Johnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.
Top 10 Pharmaceutical Giants' R&D Investments in 2024 Market Trend In 2024, pharmaceutical giants face a quiet battle over innovation and efficiency. From Merck’s 41% R&D drop to AbbVie’s bold growth, their strategies and investments reveal shifting power in the industry. A glimpse into the future of drug development.
2024 Global CAR-T Sales Performance CAR-T Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
Top 10 Global Pharmaceutical Giants in Oncology Business for 2024 Oncology Discover the top 10 pharmaceutical giants leading the oncology industry in 2024. From Merck's dominance with Keytruda to AstraZeneca's rise, these companies are making strides in cancer treatment, innovation, and growth.
2024 FDA Issued CRLs FDA The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
Johnson & Johnson 2024 Q4 Financial Report Financial statements Johnson & Johnson's 2024 financial report reveals a 4.3% revenue increase, with Daratumumab (Darzalex) reaching $11.67B and Carvykti seeing a 92.7% growth. Key oncology, immunology, and neuroscience advancements also highlighted.
Top 10 Immunology Drugs to Watch in 2024 AbbVie Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a